Can an immune booster shrink Hard-to-Treat stomach tumors?
NCT ID NCT04603040
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal is to see how many patients experience tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental immunotherapy drug called toripalimab (also known as Tuoyi)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced stomach cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Affiliated Hospital of Qingdao University
Qingdao, China
-
Affiliated Tumor Hospital of Guangzhou Medical University
Guangzhou, China
-
Affiliated Tumor Hospital of Harbin Medical University
Harbin, China
-
Anhui Provincial Hospital
Hefei, China
-
First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
Fujian Provincial Cancer Hospital
Fuzhou, China
-
Guangdong Provincial People's Hospital
Guangzhou, China
-
Henan Cancer Hospital
Henan, China
-
Jiangsu Cancer Hospital
Nanjing, China
-
Jiangxi Provincial Cancer Hospital
Nanchang, China
-
Nantong Tumor Hospital
Nantong, China
-
Peking University International Hospital
Beijing, China
-
Second Affiliated Hospital of Anhui Medical University
Hefei, China
-
Shandong Cancer Hospital
Jinan, China
-
Shanxi Cancer Hospital
Taiyuan, China
-
Shengjing Hospital of China Medical University
Shenyang, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, China
-
The First Affiliated Hospital of Bengbu Medical College
Hefei, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
-
The First Affiliated Hospital of Nanchang University Junhe Li
Nanchang, China
-
The First Affiliated Hospital of Nanhua University
Hengyang, China
-
The First Affiliated Hospital of Soochow University
Suzhou, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
-
The First Affiliated Hospital of Xinjiang Medical University
Xinjiang, China
-
The First Affiliated Hospital of Zhejiang University Medical College
Hangzhou, China
-
The First Hospital of Jilin University
Ch’ang-ch’un, China
-
The Second Affiliated Hospital of Soochow University
Suzhou, China
-
The first Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
-
The sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
-
Union Hospital affiliated to Fujian Medical University
Fuzhou, China
-
Xuzhou Central Hospital
Xuzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China
-
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital
Hangzhou, China
-
Zhengzhou Central Hospital
Zhengzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.